Huwentoxin XVI Mesh use however did not come without cost

Mesh use, however, did not come without cost. The FDA notification of 2008 warned of mesh-related complications, vaginal erosions, infections, pain, urinary problems, and recurrent symptoms. Several prior studies have examined Huwentoxin XVI effect of the FDA notification on mesh use in POP surgery. Reynolds et al, for example, first studied the near-term effect of the FDA notification on mesh use in POP surgery using Medicare claims data, finding no difference in transvaginal mesh use up to the third quarter of 2009.4 Similarly, Elterman et al examined case logs from the American Board of Urology for 2003-2013, reporting that the use of transvaginal mesh in POP surgery increased rapidly initially and then remained constant between 2008 and 2013.8 Jonsson Funk et al also examined vaginal mesh use in commercial and Medicare claims databases between 2005 and 2010 and found that the use of transvaginal mesh increased during polyp period, encompassing 75% of all vaginal POP reconstructive procedures.9